The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating
the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as
initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD
free survival at Day 56 post randomization.
Phase:
Phase 3
Details
Lead Sponsor:
Medical College of Wisconsin
Collaborators:
National Cancer Institute (NCI) National Heart, Lung, and Blood Institute (NHLBI)